HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced financial results for its Q2 and H1 2024 ending June 30, 2024. The announcement noted that the company achieved significant cost reductions, leading to an 8% quarter-over-quarter improvement in its loss from operations to $1.08 million in Q2 2024 from $1.18 million in Q1 2024. This improvement reflects HealthLynked’s ongoing efforts to streamline operations and transition its revenue streams from legacy clinical operations to app-based services. In addition, the company reported revenue of $0.78 million in Q2 2024 and $1.80 million in H1 2024. Its total operating expenses decreased by 25% in Q2 2024 compared to Q2 2023 and by 24% in H1 2024 compared to H1 2023. The net loss was $1.54 million in Q2 2024 and $2.93 million in H1 2024.
“Our continued focus on cost reduction has been crucial in setting a strong foundation for our transition towards app-based technology services. Additionally, our recent partnerships, which have expanded our telemedicine services nationwide and introduced prescription discounts through RxSpark, are pivotal steps in enhancing our offerings. We believe that these strategic initiatives will unlock significant growth opportunities and lead to better healthcare outcomes for our members.”
To view the full press release, visit https://ibn.fm/I60Ae
About HealthLynked Corp.
HealthLynked is committed to revolutionizing healthcare on a global scale. Its mission is twofold: to transform the healthcare landscape into a system characterized by exceptional efficiency and superior patient care, and to cultivate a patient-centric network that places individuals at the forefront of their health management. By integrating cutting-edge technology and fostering connectivity, HealthLynked enables patients not just to participate in their healthcare journey, but also to contribute actively to medical research. This innovative approach facilitates the development of treatments for life-altering diseases and accelerates medical breakthroughs.
The company’s network empowers patients with unprecedented control over their medical data, promoting an environment of collaboration where each contribution has the potential to drive significant advancements in health and wellness. Through this pioneering model, HealthLynked is dedicated to securing a healthier future for generations to come, making each patient not only a beneficiary of this system but also a contributor to the global health community.
NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
